Melodia Therapeutics is a startup based in Switzerland.
Based in Switzerland, Melodia Therapeutics is a startup.
Melodia Therapeutics is a Basel-based biotech developing a next-generation DPP1 inhibitor to treat severe neutrophil-driven inflammatory diseases. Their program focuses on a selective, non-covalent mechanism of DPP1 inhibition and targets respiratory, dermatologic and systemic inflammatory disorders.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.